Genfit(US:GNFT)2025-04-29 19:10Financial Reporting - GENFIT filed its 2024 Universal Registration Document and Annual Report on Form 20-F for the year ended December 31, 2024[3]. - The 2024 Universal Registration Document includes the annual financial report and management report[5]. - The annual reports are available for public access on GENFIT's website and regulatory authorities' websites[4]. Research and Development - The company has a diversified R&D portfolio focusing on Acute-on-Chronic Liver Failure (ACLF) with five assets under development[6]. - Elafibranor (Iqirvo®) received accelerated approval from the FDA, EMA, and MHRA for Primary Biliary Cholangitis (PBC)[6]. - GENFIT's diagnostic franchise includes NIS2+® for Metabolic dysfunction-associated steatohepatitis (MASH) and TS-01 for blood ammonia levels[6]. Shareholder Information - Ipsen acquired an 8% stake in GENFIT, becoming one of its largest shareholders in 2021[6]. - GENFIT is listed on both Nasdaq and Euronext markets[6]. Corporate Overview - The company is headquartered in Lille, France, with additional offices in Paris, Zurich, and Cambridge, MA[6]. Risk Factors - Forward-looking statements highlight risks related to drug development, regulatory approvals, and capital raising[7].